tbuckley/cabot-search huggingface dataset:
Henri Ghéon, 1875–1944
Authors: William L. Cooke
Journal: New England Journal of Medicine (1965)

HENRI-LéON Vangeon, better known as Henri Ghéon, was a versatile and prolific man of letters. He was not only a physician but also a painter, poet, pianist, actor, producer and critic. An ardent nationalist, he contributed articles to the royalist-sympathizing Action Française, and, most significantly, he was totally dedicated to restoring the integrity of dramatic art in France.Ghéon's medical career came in the most tumultuous period of his life and remained peripheral to his other interests. He undertook the pursuit of a medical education partly to satisfy his family's high ambitions for him and partly to meet the demands . . .
Association of Religious Service Attendance With Mortality Among Women
Authors: Shanshan Li, Meir J. Stampfer, David R. Williams, Tyler J. VanderWeele
Journal: JAMA Internal Medicine (2016)

Studies on the association between attendance at religious services and mortality often have been limited by inadequate methods for reverse causation, inability to assess effects over time, and limited information on mediators and cause-specific mortality.To evaluate associations between attendance at religious services and subsequent mortality in women.Attendance at religious services was assessed from the first questionnaire in 1992 through June 2012, by a self-reported question asked of 74 534 women in the Nurses' Health Study who were free of cardiovascular disease and cancer at baseline. Data analysis was conducted from return of the 1996 questionnaire through June 2012.Cox proportional hazards regression model and marginal structural models with time-varying covariates were used to examine the association of attendance at religious services with all-cause and cause-specific mortality. We adjusted for a wide range of demographic covariates, lifestyle factors, and medical history measured repeatedly during the follow-up, and performed sensitivity analyses to examine the influence of potential unmeasured and residual confounding.Among the 74 534 women participants, there were 13 537 deaths, including 2721 owing to cardiovascular deaths and 4479 owing to cancer deaths. After multivariable adjustment for major lifestyle factors, risk factors, and attendance at religious services in 1992, attending a religious service more than once per week was associated with 33% lower all-cause mortality compared with women who had never attended religious services (hazard ratio, 0.67; 95% CI, 0.62-0.71; P < .001 for trend). Comparing women who attended religious services more than once per week with those who never attend, the hazard ratio for cardiovascular mortality was 0.73 (95% CI, 0.62-0.85; P < .001 for trend) and for cancer mortality was 0.79 (95% CI, 0.70-0.89; P < .001 for trend). Results were robust in sensitivity analysis. Depressive symptoms, smoking, social support, and optimism were potentially important mediators, although the overall proportion of the association between attendance at religious services and mortality was moderate (eg, social support explained 23% of the effect [P = .003], depressive symptoms explained 11% [P < .001], smoking explained 22% [P < .001], and optimism explained 9% [P < .001]).Frequent attendance at religious services was associated with significantly lower risk of all-cause, cardiovascular, and cancer mortality among women. Religion and spirituality may be an underappreciated resource that physicians could explore with their patients, as appropriate.
Feasibility and Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in High-Risk AML: Real-Life Perspective from a Single Institution
Authors: Marina Diaz-Beya, Miguel Angel Torrente, Alfonso Ardilla, Carles Serra, Nuria Martinez, Maria Suarez-Lledo, Carmen Martinez, Francesc Fernandez, Laura Rosiñol, Gonzalo Gutierrez, Pedro Marin, Marta Pratcorona, Nuria Mariegues, Noemi Llobet, Marta Bistagne, Enric Carreras, Alvaro Urbano-Ispizua, Montserrat Rovira, Jordi Esteve
Journal: Blood (2015)
The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin's disease.
Authors: J A Kant, S M Hubbard, D L Longo, R M Simon, V T DeVita, E S Jaffe
Journal: Journal of Clinical Oncology (1986)

Patients with Hodgkin's disease of the lymphocyte-depleted subtype (LDHD) have been said to have a poor prognosis. However, reports of this subtype are complicated by the fact that the histologic diagnosis of LDHD is often not straightforward, and its distinction from aggressive non-Hodgkin's lymphomas (NHL) can be difficult. We have reviewed our patients with LDHD at the National Cancer Institute (NCI) in light of an additional decade of experience with neoplastic and non-neoplastic conditions mimicking Hodgkin's disease. Of 198 patients who received MOPP (mechlorethamine, vincristine, procarbazine, prednisone) treatment at the NCI for Hodgkin's disease between 1964 and 1976, 43 (22%) were originally classified as LDHD. The initial diagnostic biopsies from 39 of these patients were reviewed and revealed ten with NHL, nine with LDHD, and 13 with nodular sclerosing Hodgkin's disease of the lymphocyte-depleted subtype (NSLD). The other seven patients had Hodgkin's disease without a lymphocyte-depleted component. The NHL patients were further subclassified as diffuse, large-cell (two cases) and large-cell, immunoblastic (eight cases). The pathologic review was done without knowledge of clinical features which were examined after review in the three major subgroups. Of ten patients with NHL, only three had a complete remission (CR), and median survival was 7 months. Nine of the NHL patients presented with features that are unusual for patients with Hodgkin's disease, such as bulky abdominal disease, epitrochlear lymphade-nopathy, or hypercalcemia. CRs were attained by 67% and 85% of patients in the LDHD and NSLD groups, respectively: median survival had not been reached in either group with a median of 14 years of follow-up. Lymphocyte-depleted Hodgkin's disease, adequately treated, is in our limited group of patients no worse than other histopathologic subtypes of Hodgkin's disease. The erroneous inclusion of patients with high-grade NHLs into this subtype of Hodgkin's disease may be one reason for earlier literature reports of its more aggressive nature. The diagnosis of LDHD should be made cautiously, particularly in patients with clinical features that are unusual for Hodgkin's disease at presentation.
Chemotherapy, tamoxifen, and breast cancer: reconciling differences.
Authors: H Pourquier
Journal: Journal of Clinical Oncology (1991)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1991.9.3.526 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 1999722 Chemotherapy, tamoxifen, and breast cancer: reconciling differences. H PourquierxH PourquierSearch for articles by this author https://doi.org/10.1200/JCO.1991.9.3.526 First Page PDF © 1991 by American Society of Clinical Oncology
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression
Authors: Saby George, Robert J. Motzer, Hans J. Hammers, Bruce G. Redman, Timothy M. Kuzel, Scott S. Tykodi, Elizabeth R. Plimack, Joel Jiang, Ian M. Waxman, Brian I. Rini
Journal: JAMA Oncology (2016)

Response patterns with immunotherapy may differ from those of other treatments. This warrants further investigation because some patients may benefit from continued immunotherapy beyond Response Evaluation Criteria in Solid Tumors (RECIST)-defined first progression.To evaluate the safety and potential benefit of treatment with nivolumab, a programmed cell death 1 immune checkpoint inhibitor, beyond investigator-assessed first progression in patients with metastatic renal cell carcinoma (mRCC).Subgroup analysis of a blinded, randomized, multicenter, phase 2 dose-ranging trial initiated May 31, 2011, including patients with clear-cell mRCC previously treated with antiangiogenic therapy. Data cutoffs for this subgroup analysis were May 15, 2013, for progression-free survival and objective response rate and March 5, 2014, for overall survival and duration of response. In this analysis, patients treated beyond first progression received their last dose of nivolumab more than 6 weeks after RECIST-defined progression, and patients not treated beyond first progression discontinued nivolumab before or at RECIST-defined progression.Nivolumab 0.3, 2, or 10 mg/kg intravenously every 3 weeks.Safety and efficacy of nivolumab treatment.Of 168 patients (median [range] age, 61 [37-81] years; 72% male) randomized to nivolumab, 154 experienced progression (36 were treated beyond first progression, 26 were treated beyond first progression for ≤6 weeks, and 92 were not treated beyond first progression), 13 were treated and did not experience progression, and 1 was not treated. Prior to first progression, the RECIST-defined objective response rate was 14% (5 patients) and 16% (15 patients), and median progression-free survival was 4.2 (95% CI, 2.8-5.5) and 2.6 (95% CI, 1.5-3.9) months in patients treated and not treated beyond progression, respectively. Following initial progression, 25 (69%) patients treated beyond progression experienced subsequent tumor reduction or stabilization in target lesion size. The incidence of treatment-related adverse events was higher in patients treated beyond progression (n = 29 [81%]) vs those not treated beyond progression (n = 61 [66%]); however, after adjusting for length of treatment exposure, incidence was lower in patients treated beyond progression (322.9 vs 518.7 incidence rate/100 patient-years for patients treated vs not treated beyond progression).In this subgroup analysis, a proportion of patients who continued treatment beyond RECIST-defined first progression demonstrated sustained reductions in tumor burden or stabilization in the size of target lesions, with an acceptable safety profile. Further analysis will help define the clinical benefit for patients with mRCC treated with nivolumab beyond progression.clinicaltrials.gov Identifier: NCT01354431.
Enhanced antagonism of BST-2 by a neurovirulent SIV envelope
Authors: Kenta Matsuda, Chia-Yen Chen, Sonya Whitted, Elena Chertova, David J. Roser, Fan Wu, Ronald J. Plishka, Ilnour Ourmanov, Alicia Buckler-White, Jeffrey D. Lifson, Klaus Strebel, Vanessa M. Hirsch
Journal: Journal of Clinical Investigation (2016)

Current antiretroviral therapy (ART) is not sufficient to completely suppress disease progression in the CNS, as indicated by the rising incidence of HIV-1-associated neurocognitive disorders (HAND) among infected individuals on ART. It is not clear why some HIV-1-infected patients develop HAND, despite effective repression of viral replication in the circulation. SIV-infected nonhuman primate models are widely used to dissect the mechanisms of viral pathogenesis in the CNS. Here, we identified 4 amino acid substitutions in the cytoplasmic tail of viral envelope glycoprotein gp41 of the neurovirulent virus SIVsm804E that enhance replication in macrophages and associate with enhanced antagonism of the host restriction factor BM stromal cell antigen 2 (BST-2). Rhesus macaques were inoculated with a variant of the parental virus SIVsmE543-3 that had been engineered to contain the 4 amino acid substitutions present in gp41 of SIVsm804E. Compared with WT virus-infected controls, animals infected with mutant virus exhibited higher viral load in cerebrospinal fluid. Together, these results are consistent with a potential role for BST-2 in the CNS microenvironment and suggest that BST-2 antagonists may serve as a possible target for countermeasures against HAND.
PWE-410 Initial UK experience with transversus abdominus muscle release for posterior components separation in abdominal wall reconstruction of large or complex ventral hernias. a combined approach by general and plastic surgeons
Authors: N Appleton, K Anderson, K Hancock, M Scott, C Walsh
Journal: Gut (2015)

<h3>Introduction</h3> Large complicated ventral hernias are an increasingly common problem following laparotomy and particularly laparostomy. Moreover, they are often seen in patients with significant co-morbidities who may have or need to have stomas. Repair with bridging is associated with high recurrence rates and makes surgical risk unattractive. The transversus abdominis muscle release (TAMR) is a recently described modification of posterior components separation for repair of such hernias. We describe our initial experience with TAMR and sublay mesh to facilitate abdominal wall reconstruction. <h3>Method</h3> A retrospective review of consecutive patients undergoing TAMR performed synchronously by colorectal and plastic surgeons since June 2013. <h3>Results</h3> Twelve consecutive patients had their ventral hernias repaired using the TAMR technique from June 2013 to June 2014. Median body mass index was 30.8 kg/m<sup>2</sup>(range 19.0–34.4 kg/m<sup>2</sup>). Four had a previous ventral hernia repair. Three had previous laparostomies. Four had previous stomas and three had stomas created at the time of the abdominal wall reconstruction. Average and range of transverse distance between the recti was 13 cm (3–20 cm). Median operative time was 383 min (range 150–550 min), and mesh size was 950 cm<sup>2</sup>(532–2400 cm<sup>2</sup>). Primary midline fascial closure was possible in all cases with no bridging. Median length of hospital stay was 7.5 days (4–17 days). Three developed minor abdominal wall wound complications. At short-term review (median 3.5 months), there have been no significant wound problems, no mesh infections or explants and none have developed recurrence of their ventral hernia. <h3>Conclusion</h3> We believe TAMR offers significant advantages over other forms of components separation in this patient group. The technique can be adopted successfully in UK practice and combined gastrointestinal and plastic surgeon operating yields good early results. <h3>Disclosure of interest</h3> None Declared.
Hepatitis B surface antigen loss: Not all that we hoped it would be
Authors: Michael H. Nathanson, Norah Terrault
Journal: Hepatology (2016)

1Yale University School of MedicineNew HavenCT 2University of CaliforniaSan FranciscoCA *ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:Michael H. Nathanson, M.D., Ph.D.Digestive Diseases Section, Yale University School of Medicine300 Cedar Street, Room TAC S241DNew Haven, CT 06520‐8019Tel: +1‐203‐785‐7312E‐mail: [email protected]
Abnormal Microsomal Detoxification Implicated in Fanconi Anemia Group C by Interaction of the FAC Protein With NADPH Cytochrome P450 Reductase
Authors: Frank A.E. Kruyt, Taizo Hoshino, Johnson M. Liu, Pius Joseph, Anil K. Jaiswal, Hagop Youssoufian
Journal: Blood (1998)
476 WHICH CORRELATION AMONG HISTOLOGICAL ASSESSMENT OF FIBROSIS, NON-INVASIVE MARKERS AND PORTAL HYPERTENSION IN HCV TRANSPLANTED PATIENTS?
Authors: G. Isgro, V. Calvaruso, P. Manousou, T.V. Luong, L. Andreana, S. Maimone, L. Makalanda, L. Marelli, D. Patch, N. Davies, J. O'Beirne, A.P. Dhillon, A.K. Burroughs
Journal: Journal of Hepatology (2010)
Dietary Interventions, Cardiovascular Aging, and Disease
Authors: Hamed Mirzaei, Stefano Di Biase, Valter D. Longo
Journal: Circulation Research (2016)

Recent studies indicate that dietary interventions have the potential to prevent and even treat cardiovascular disease, which is the leading cause of death. Many of these studies have focused on various animal models that are able to recreate one or more conditions or elevate risk factors that characterize the disease. Here, we highlight macronutrient-focused interventions in both mammalian model organisms and humans with emphasis on some of the most relevant and well-established diets known to be associated with cardiovascular disease prevention and treatment. We also discuss more recent dietary interventions in rodents, monkeys, and humans, which affect atherosclerosis and cardiovascular diseases with focus on those that also delay aging.
High-Dose Interleukin-2 (Hd Il2) Armed with Pathology-Based Selection Criteria: a Real Option in Treatment of Metastatic Renal Cell Carcinoma (Mrcc) After Targeted Therapy
Authors: S. Chow, V. Galvis, M. Evans, K. Chan, A. Spencer-Shaw, R. Leach, E.K. Keene, A. Shablak, J. Shanks, F. Thistlethwaite, R. Hawkins
Journal: Annals of Oncology (2014)
Abstract 15914: Conditional Deletion of Epsins Attenuates Atherosclerosis in ApoE-Deficient Mouse Model
Authors: Yunzhou Dong, Hua Zhu, Xiaofeng Cai, Baojun Chang, Scott Hahn, Satish Pasula, Hong Chen
Journal: Circulation (2011)

Objective: Epsins are adaptor proteins implicated in clathrin-mediated endocytosis and membrane receptor signaling. Global deletion of epsins in mice causes embryonic lethality. Whether epsins are ...
The Coronary Circulation as a Target of Cardioprotection
Authors: Gerd Heusch
Journal: Circulation Research (2016)

The atherosclerotic coronary vasculature is not only the culprit but also a victim of myocardial ischemia/reperfusion injury. Manifestations of such injury are increased vascular permeability and edema, endothelial dysfunction and impaired vasomotion, microembolization of atherothrombotic debris, stasis with intravascular cell aggregates, and finally, in its most severe form, capillary destruction with hemorrhage. In animal experiments, local and remote ischemic pre- and postconditioning not only reduce infarct size but also these manifestations of coronary vascular injury, as do drugs which recruit signal transduction steps of conditioning. Clinically, no-reflow is frequently seen after interventional reperfusion, and it carries an adverse prognosis. The translation of cardioprotective interventions to clinical practice has been difficult to date. Only 4 drugs (brain natriuretic peptide, exenatide, metoprolol, and esmolol) stand unchallenged to date in reducing infarct size in patients with reperfused acute myocardial infarction; unfortunately, for these drugs, no information on their impact on the ischemic/reperfused coronary circulation is available.
Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain
Authors: Alberto Pineda, Juan-Manuel Sancho, Olga Garcia, Jordi Esteve, Mar Tormo, Pilar Martinez, Ferran Vall-llovera, Rodrigo Martino, Pau Montesinos, Jose Gonzalez-Campos, Juan Bergua, María Calbacho, Cristina Gil, Ana Vicent, Antònia Cladera, Jesus Hernandez, Maria-José Moreno, Alfons Serrano, Natalia Alonso, Raimundo García, Pere Barba, Angeles Fernandez, Pilar Miralles, Andrés Novo, Jose Maria Moraleda, José Ángel Hernández, Eugenia Abella, Magdalena Sanchez, Maria-Elsa Lopez, Teresa Bernal, Mª Carmen Mateos, Esperanza Lavilla, Josep-Maria Ribera
Journal: Blood (2015)
Mass Cytometry of the Human Mucosal Immune System Identifies Tissue- and Disease-Associated Immune Subsets
Authors: Vincent van Unen, Na Li, Ilse Molendijk, Mine Temurhan, Thomas Höllt, Andrea E. van der Meulen-de Jong, Hein W. Verspaget, M. Luisa Mearin, Chris J. Mulder, Jeroen van Bergen, Boudewijn P.F. Lelieveldt, Frits Koning
Journal: Immunity (2016)
Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center
Authors: Vaishali Sanchorawala, Gheorghe Doros, Karen Quillen, John Mark Sloan, Anthony C Shelton, Dina Brauneis, Kathleen T Finn, David C Seldin
Journal: Blood (2013)
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study
Authors: Jon M. Hanifin, Charles N. Ellis, Ilona J. Frieden, Regina Fölster-Holst, Linda F. Stein Gold, Angelo Secci, Angela J. Smith, Cathy Zhao, Elena Kornyeyeva, Lawrence F. Eichenfield
Journal: Journal of the American Academy of Dermatology (2016)

Peripheral leukocytes in patients with atopic dermatitis (AD) have elevated phosphodiesterase-4 activity, which is associated with production of proinflammatory mediators. OPA-15406 is a phosphodiesterase-4 inhibitor with high selectivity for phosphodiesterase-4-B.We sought to assess effectiveness and tolerability of topical OPA-15406 in patients with AD.This was a randomized, double-blind, vehicle-controlled, phase-II study. Patients 10 to 70 years of age with mild or moderate AD received topical OPA-15406 0.3% (n = 41), OPA-15406 1% (n = 43), or vehicle (n = 37) twice daily for 8 weeks.The primary end point, Investigator Global Assessment of Disease Severity score of 0 or 1 with greater than or equal to 2-grade reduction, was met at week 4 in the OPA-15406 1% group (P = .0165 vs vehicle). Mean percentage improvement from baseline Eczema Area and Severity Index score for OPA-15406 1% was notable in week 1 (31.4% vs 6.0% for vehicle; P = .0005), even larger in week 2 (39.0% vs 3.0%; P = .0001), and persisted for 8 weeks. Visual analog scale pruritus scores improved from moderate to mild within the first week in the OPA-15406 1% group (36.4% mean change; P = .0011). OPA-15406 levels in blood were negligible. Incidence of adverse events was low, with most events mild in intensity.Further confirmatory phase-III studies are required.OPA-15406 ointment may provide an effective therapeutic modality for patients with mild to moderate AD.
Iron deficiency anemia: Don’t forget gastric atrophy!
Authors: V. Maunoury, P. Bulois
Journal: Endoscopy (2007)

We read the paper by Apostolopoulos et al. with great interest [1]. In this paper, the authors point out the role of wireless capsule endoscopy in investigating unexplained iron deficiency anemia after negative standard endoscopic evaluation, and then recommend a gastrointestinal diagnostic algorithm. We agree. However, in a step by step approach to the evaluation of iron deficiency anemia, one should not forget that atrophic gastritis may be responsible for iron malabsorption. In our clinical practice, this hypothesis has to be investigated in women with iron deficiency refractory to oral supplementation. It is confirmed by high serum gastrin and is usually related to autoimmune atrophic gastritis, also called pernicious anemia or Biermer’s disease. It is related to fundic atrophy, and the patients present reduced secretion of gastric acid which compromises iron absorption. Vitamin B-12 deficiency occurs later than iron deficiency because of more abundant body reserves. Lagarde et al. recently demonstrated that iron deficiency is not rare in pernicious anemia, especially in premenopausal women, suggesting menstrual blood loss could play a role [2]. Other studies have suggested that some patients with unexplained iron deficiency anemia have presented atrophic gastritis [3] [4].